I-New Orphan Drug Designation for Treatment of Follicular Lymphoma

I-BI-1206 iyikhandidethi lezidakamizwa elihamba phambili le-BioInvent futhi okwamanje isaphenywa ezivivinyweni ezimbili zeSigaba 1/2. Enye ihlola inhlanganisela ye-BI-1206 ne-rituximab yokwelapha i-Non-Hodgkin lymphoma, ehlanganisa iziguli ezine-FL, MCL kanye ne-marginal zone lymphoma (MZL) ezibuyele emuva noma eziphikisa i-rituximab. Uhlolo lweSigaba 1/2 sesibili luphenya i-BI-1206 ngokuhlanganiswe ne-anti-PD1 yokwelapha i-Keytruda® (pembrolizumab) kumathumba aqinile.

UDkt. Wei-Wu He, uSihlalo kanye ne-CEO ye-CASI ubeke amazwana, “I-BioInvent isaqhubeka nokuthuthuka ngohlaka lokuthuthukiswa nokulawula lwe-BI-1206. Ukugunyazwa kwe-CTA e-China ngoDisemba 2021 kanye ne-FDA Orphan Drug Designation yakamuva ibonisa amandla aqinile aleli qembu lokuqala le-antibody. I-CASI inamalungelo okuhweba ase-China e-BI-1026, futhi ithimba lethu lilungiselela ucwaningo lwase-China lomtholampilo. I-CASI kanye ne-BioInvent bangozakwethu abangenazihibe futhi banomgomo ofanayo wokusiza iziguli ngobuchwepheshe obusha bokwenza imithi.”